- Oops!Something went wrong.Please try again later.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session later this month.
During the Virtual Poster Session, Catabasis and collaborators will present three posters entitled:
Baseline Characteristics of Patients Enrolled in PolarisDMD, a Phase 3 Trial of Edasalonexent for Duchenne Muscular Dystrophy. Richard S. Finkel; Craig McDonald; H. Lee Sweeney; Kathryn Wagner; Erin Neil; Maria Mancini; James MacDougall; Joanne M. Donovan.
Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function. Erika L. Finanger; Richard S. Finkel; Gihan I. Tennekoon; Krista Vandenborne; H. Lee Sweeney; Perry Shieh; Sabrina W. Yum; Maria Mancini; James MacDougall; Joanne M. Donovan.
Experience with Edasalonexent Demonstrates Ability of 4 to 7 Year Old Boys with Duchenne Muscular Dystrophy to Take Soft-gel Capsules in Trials. Maria Mancini; Gigi Shafai; Joanne M. Donovan; Sachin Chandran; Richard S. Finkel.
The poster session will be available to registered conference attendees and will be made available under "Our Science" on the company website at www.catabasis.com.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule designed to inhibit NF-kB that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of their underlying mutation. In DMD the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. Our ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy and safety of edasalonexent for registration purposes. Edasalonexent is also being dosed in the GalaxyDMD open-label extension trial. In our MoveDMD Phase 2 trial and open-label extension, we observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results, please visit www.catabasis.com.
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200417005027/en/
Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971